The prognostic value of plasma galectin-3 in chronic heart failure patients is maintained when treated with mineralocorticoid receptor antagonists

PloS One
François KoukouiPhilippe Rouet

Abstract

Galectin-3 (Gal-3) is considered as a myocardial fibrosis biomarker with prognostic value in heart failure (HF). Since aldosterone is a neurohormone with established fibrotic properties, we aimed to investigate if mineralocorticoid receptor antagonists (MRAs) would modulate the prognostic value of Gal-3. The IBLOMAVED cohort comprised 427 eligible chronic HF patients (CHF) with echocardiography and heart failure biomarkers assessments (BNP). After propensity score matching CHF patients for cardiovascular risk factors, to form balanced groups, Gal-3 levels were measured at baseline in plasma from patients treated with MRAs (MRA-Plus, n=101) or not (MRA-Neg, n=101). The primary end point was all-cause mortality with a follow-up of 3 years. Gal-3 in plasma from these patients were similar with median values of 14.0 ng/mL [IQR, 9.9-19.3] and 14.4 ng/mL [IQR, 12.3-19.8] (P = 0.132) in MRA-Neg and MRA-Plus, respectively. Patients with Gal-3 ≤17.8 ng/mL had an HR of 1 (reference group) and 1.5 [0.4-5.7] in MRA-Neg and MRA-Plus, respectively (p=0.509). Patients with Gal-3 ≥ 17.8 ng/mL had an HR of 7.4 [2.2-24.6] and 9.0 [2.9-27.8] in MRA-Plus and MRA-Neg, respectively (p=0.539) and a median survival time of 2.4 years [95%CI,1.8-2.4]. M...Continue Reading

References

Sep 12, 2002·Biochimica Et Biophysica Acta·Douglas N W Cooper
Jun 6, 2003·The Journal of Clinical Endocrinology and Metabolism·Perrin C White
Feb 16, 2006·Biochimica Et Biophysica Acta·Jerka DumicMirna Flögel
Mar 22, 2006·Proceedings of the National Academy of Sciences of the United States of America·Neil C HendersonTariq Sethi
Sep 19, 2006·Journal of the American College of Cardiology·Roland R van KimmenadeYigal M Pinto
Jan 19, 2008·The American Journal of Pathology·Neil C HendersonTariq Sethi
Jul 23, 2008·Perspectives in Vascular Surgery and Endovascular Therapy·Kimon Bekelis, Nicos Labropoulos
Aug 4, 2009·European Journal of Heart Failure·Rudolf A de BoerDirk J van Veldhuisen
Sep 15, 2009·Clinica Chimica Acta; International Journal of Clinical Chemistry·Yen-Hung LinMing-Fong Chen
Feb 5, 2010·Clinical Research in Cardiology : Official Journal of the German Cardiac Society·Dirk J A LokDirk J van Veldhuisen
Dec 30, 2010·Annals of Medicine·Rudolf A de BoerDirk J van Veldhuisen
Jul 7, 2011·PloS One·Fatima SmihPhilippe Rouet
Oct 27, 2011·Journal of Internal Medicine·R A de BoerP van der Harst
Nov 19, 2011·American Journal of Respiratory and Critical Care Medicine·Alison C MackinnonTariq Sethi
Sep 4, 2012·Journal of the American College of Cardiology·Jennifer E HoDaniel Levy
Nov 3, 2012·Arteriosclerosis, Thrombosis, and Vascular Biology·Laurent CalvierNatalia López-Andrés
Nov 29, 2012·JAMA : the Journal of the American Medical Association·Adrian F HernandezLesley H Curtis
Feb 12, 2013·Circulation. Heart Failure·A Rogier van der VeldeRudolf A de Boer
Jun 7, 2013·Circulation·UNKNOWN WRITING COMMITTEE MEMBERSUNKNOWN American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines
Nov 12, 2013·International Journal of Cardiology·Francisco Javier Carrasco-SánchezJuan Ignacio Pérez-Calvo
May 16, 2014·Critical Pathways in Cardiology·William Frank Peacock, Salvatore DiSomma
Jun 3, 2014·Clinical Chemistry and Laboratory Medicine : CCLM·Jelena P SeferovicSalvatore Di Somma

❮ Previous
Next ❯

Citations

Apr 14, 2017·Journal of Hypertension·T N A Daniëlle van den BergNiels P Riksen
Sep 29, 2019·Acta Cardiologica·Manon BarutautPhilippe Rouet
Oct 11, 2019·Clinical Research in Cardiology : Official Journal of the German Cardiac Society·Xi ZhangChamindie Punyadeera
Dec 6, 2017·International Journal of Molecular Medicine·Rui DongHui Yuan
May 30, 2020·Journal of the American College of Cardiology·Vivek NarayanBonnie Ky
Dec 7, 2019·International Journal of Cardiology·Manon BarutautPhilippe Rouet

❮ Previous
Next ❯

Clinical Trials Mentioned

NCT01024049

Software Mentioned

Statistical R
Medcalc
Neg
MatchIt
IBLOMAVED
Plus
MRA

Related Concepts

Related Feeds

Cardiomyopathy

Cardiomyopathy is a disease of the heart muscle, that can lead to muscular or electrical dysfunction of the heart. It is often an irreversible disease that is associated with a poor prognosis. There are different causes and classifications of cardiomyopathies. Here are the latest discoveries pertaining to this disease.

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.

Biomarkers for Cardiovascular Risk Assessment

Sensitive and accurate biomarkers used in cardiovascular risk prediction can potentially be used to manage the risk of cardiovascular disease. Discover the latest research on Biomarkers for Cardiovascular Risk Assessment here. Discover the latest research on Biomarkers for Cardiovascular Risk Assessment here.

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

Cardiovascular Diseases: Risk Factors

Cardiovascular disease is a significant health concern. Risk factors include hypertension, obesity, dyslipidemia and smoking. Women who are postmenopausal are at an increased risk of heart disease. Here is the latest research for risk factors of cardiovascular disease.